Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
* Reuters is not responsible for the content in this press release.
New Device Significantly Simplifies the Treatment of Abdominal Aortic
Aneurysms
IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq:
ELGX) today announced the full commercial launch of the InutiTrak(TM) Express
Delivery System for the endovascular treatment of large neck abdominal aortic
aneurysms (AAA). The IntuiTrak family of devices features low profile,
minimally invasive endovascular delivery systems that enhance vascular
accessibility and maneuverability while simplifying the deployment of the
Company's Powerlink stent graft products. As the newest addition to the
IntuiTrak platform, IntuiTrak Express incorporates novel design and deployment
features that enable the delivery of the Powerlink XL stent graft through the
IntuiTrak 19Fr introducer sheath. This is the lowest profile delivery system
currently available in the US for the endovascular repair of AAA in patients
with aortic necks up to 32mm in diameter.
John McDermott, President and CEO of Endologix, said, "IntuiTrak Express
expands our portfolio into a comprehensive suite of products that address a
broad range of patient anatomies and physician preferences. Most importantly,
it allows physicians to easily deliver and deploy our Powerlink XL stent graft
through a single 19Fr introducer sheath, which has demonstrated the potential
to reduce procedure times while minimizing blood loss and vessel trauma. We
believe this will allow us to gain a greater share of physicians' AAA
procedures based upon the ease of use and strong clinical outcomes achieved in
patients with large aortic necks and other AAA anatomies. Early physician
feedback on IntuiTrak Express was very positive during its limited release, so
we accelerated the full commercial launch ahead of our original guidance to
launch in the third quarter of this year."
The IntuiTrak Express Delivery System will be featured from June 11-14, 2009
at the Annual Meeting of the Society for Vascular Surgery (SVS) in Denver,
Colorado. The Company's complete product portfolio will also be on display at
the SVS meeting in the Company's booth #625.
About Endologix
Endologix, Inc. develops and manufactures minimally invasive treatments for
aortic disorders. The Company's flagship product is the Powerlink(R) System,
which is an endovascular stent graft for the treatment of abdominal aortic
aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement. Once AAA
develops, it continues to enlarge and, if left untreated, becomes increasingly
susceptible to rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S. Additional
information can be found on Endologix's Web site at www.endologix.com.
Except for historical information contained herein, this news release contains
forward-looking statements, specifically with respect to the full
commercialization of the IntuiTrak Express Delivery System for the Powerlink
XL, accuracy of which are necessarily subject to risks and uncertainties, all
of which are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual results to
differ materially from anticipated results, including the success of sales
efforts for the Powerlink System and related new products, product research
and development efforts, and other economic, business, competitive and
regulatory factors. The Company undertakes no obligation to update its
forward looking statements. Please refer to the Company's Annual Report on
Form 10-K for the year ended December 31, 2008, and the Company's other
filings with the Securities and Exchange Commission, for more detailed
information regarding these risks and other factors that may cause actual
results to differ materially from those expressed or implied.
COMPANY CONTACT: INVESTOR CONTACTS:
---------------- ------------------
Endologix, Inc. The Ruth Group
John McDermott, CEO Nick Laudico (646) 536-7030
(949) 595-7200 Zack Kubow (646) 536-7020
www.endologix.com
SOURCE Endologix, Inc.
John McDermott, CEO of Endologix, Inc., +1-949-595-7200; or Investors, Nick
Laudico, +1-646-536-7030, or Zack Kubow, +1-646-536-7020, both of The Ruth
Group for Endologix, Inc.
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters